{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:20:27Z","timestamp":1787642427573,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["1R37CA288492"],"award-info":[{"award-number":["1R37CA288492"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10549-026-08043-y","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:10:28Z","timestamp":1786349428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare"],"prefix":"10.1007","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6920-8526","authenticated-orcid":false,"given":"Laura C.","family":"Pinheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjile","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystal A.","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Tonorezos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri I.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"11","key":"8043_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/jnci\/djac158","volume":"14","author":"L Gallicchio","year":"2022","unstructured":"Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A (2022) Estimation of the Number of Individuals Living With Metastatic Cancer in the United States. J Natl Cancer Inst Nov 14(11):1476\u20131483. https:\/\/doi.org\/10.1093\/jnci\/djac158","journal-title":"J Natl Cancer Inst Nov"},{"issue":"1","key":"8043_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, Danysh HE, Singh J et al (2020) Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat Aug 183(1):23\u201339. https:\/\/doi.org\/10.1007\/s10549-020-05754-8","journal-title":"Breast Cancer Res Treat Aug"},{"key":"8043_CR3","doi-asserted-by":"publisher","unstructured":"Skeoch S, Weatherley N, Swift AJ et al (2018) Drug-induced interstitial lung disease: a systematic review. J Clin Med Oct 15(10). https:\/\/doi.org\/10.3390\/jcm7100356","DOI":"10.3390\/jcm7100356"},{"issue":"1","key":"8043_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11596-022-2693-2","volume":"43","author":"HP Dai","year":"2023","unstructured":"Dai HP, Ma F, Ren YH, Chen SS, Li YQ (2023) Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. Curr Med Sci Feb 43(1):1\u201312. https:\/\/doi.org\/10.1007\/s11596-022-2693-2","journal-title":"Curr Med Sci Feb"},{"key":"8043_CR5","doi-asserted-by":"publisher","unstructured":"Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V (2022) Drug-induced interstitial lung disease. Eur Respir J Oct 60(4). https:\/\/doi.org\/10.1183\/13993003.02776-2021","DOI":"10.1183\/13993003.02776-2021"},{"issue":"5","key":"8043_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MCP.0000000000001095","volume":"1","author":"KI Aronson","year":"2024","unstructured":"Aronson KI, Swigris JJ, Wijsenbeek M (2024) Integrating the assessment of quality of life in care and research in pulmonary fibrosis. Curr Opin Pulm Med Sep 1(5):508\u2013515. https:\/\/doi.org\/10.1097\/MCP.0000000000001095","journal-title":"Curr Opin Pulm Med Sep"},{"issue":"2","key":"8043_CR7","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","volume":"15","author":"KI Aronson","year":"2021","unstructured":"Aronson KI, Danoff SK, Russell AM et al (2021) Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med Jul 15(2):e3\u2013e23. https:\/\/doi.org\/10.1164\/rccm.202105-1193ST","journal-title":"Am J Respir Crit Care Med Jul"},{"key":"8043_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/tbcr-23-14","volume":"4","author":"Y Song","year":"2023","unstructured":"Song Y, Lv Y (2023) Antibody-drug conjugate monotherapy refines the oncological efficacy as compared to therapy of physicians\u2019 choices in advanced breast cancers: a systematic review and meta-analysis. Transl Breast Cancer Res 4:11. https:\/\/doi.org\/10.21037\/tbcr-23-14","journal-title":"Transl Breast Cancer Res"},{"issue":"1","key":"8043_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s12672-024-01705-7","volume":"27","author":"JY Zhu","year":"2024","unstructured":"Zhu JY, Jiang RY, Zhang HP et al (2024) Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer. Discov Oncol Dec 27(1):843. https:\/\/doi.org\/10.1007\/s12672-024-01705-7","journal-title":"Discov Oncol Dec"},{"key":"8043_CR10","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/j.eclinm.2025.103160","volume":"82","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Li Y, Zhu C et al (2025) Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study. EClinicalMedicine Apr 82:103160. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103160","journal-title":"EClinicalMedicine Apr"},{"issue":"3","key":"8043_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-022-06738-6","volume":"196","author":"JW Law","year":"2022","unstructured":"Law JW, Campbell A, Weller C et al (2022) Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis. Breast Cancer Res Treat Dec 196(3):603\u2013611. https:\/\/doi.org\/10.1007\/s10549-022-06738-6","journal-title":"Breast Cancer Res Treat Dec"},{"key":"8043_CR12","doi-asserted-by":"publisher","unstructured":"Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):Iv\u20133\u201318. https:\/\/doi.org\/10.1097\/01.Mlr.0000020942.47004.03","DOI":"10.1097\/01.Mlr.0000020942.47004.03"},{"key":"8043_CR13","volume-title":"SEER Cancer Statistics Review 1974\u20132014","author":"N Howlader","year":"2015","unstructured":"Howlader N, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2015) SEER Cancer Statistics Review 1974\u20132014. National Cancer Institute, Bethesda, MD"},{"issue":"7","key":"8043_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1513\/AnnalsATS.202102-222OC","volume":"19","author":"D Singer","year":"2022","unstructured":"Singer D, Bengtson LGS, Conoscenti CS et al (2022) Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States. Ann Am Thorac Soc Jul 19(7):1112\u20131121. https:\/\/doi.org\/10.1513\/AnnalsATS.202102-222OC","journal-title":"Ann Am Thorac Soc Jul"},{"issue":"12","key":"8043_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/17425255.2022.2162383","volume":"18","author":"WP Yong","year":"2022","unstructured":"Yong WP, Teo FS, Teo LL et al (2022) Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opin Drug Metab Toxicol Dec 18(12):805\u2013815. https:\/\/doi.org\/10.1080\/17425255.2022.2162383","journal-title":"Expert Opin Drug Metab Toxicol Dec"},{"issue":"6","key":"8043_CR16","doi-asserted-by":"publisher","first-page":"102043","DOI":"10.1016\/j.esmoop.2023.102043","volume":"8","author":"D Wekking","year":"2023","unstructured":"Wekking D, Porcu M, Pellegrino B et al (2023) Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open Dec 8(6):102043. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102043","journal-title":"ESMO Open Dec"},{"issue":"6","key":"8043_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2023) NCCN Guidelines(R) Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw Jun 21(6):594\u2013608. https:\/\/doi.org\/10.6004\/jnccn.2023.0031","journal-title":"J Natl Compr Canc Netw Jun"},{"issue":"2","key":"8043_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-024-07586-2","volume":"210","author":"J Williamson","year":"2025","unstructured":"Williamson J, Kelley K, Scholand MB et al (2025) Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan. Breast Cancer Res Treat Apr 210(2):487\u2013491. https:\/\/doi.org\/10.1007\/s10549-024-07586-2","journal-title":"Breast Cancer Res Treat Apr"},{"key":"8043_CR19","doi-asserted-by":"publisher","unstructured":"Moore H, Shofer S, Guisinger A, Broadwater G, Force J, Sammons S, Anders C, Westbrook K (2021) Abstract PS13-33: feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan. Cancer Res 81(4_Supplement). https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PS13-33","DOI":"10.1158\/1538-7445.SABCS20-PS13-33"},{"issue":"1","key":"8043_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-018-5058-6","volume":"174","author":"E Lidbrink","year":"2019","unstructured":"Lidbrink E, Chmielowska E, Otremba B et al (2019) A real-world study of cardiac events in >\u20093700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Treat Feb 174(1):187\u2013196. https:\/\/doi.org\/10.1007\/s10549-018-5058-6","journal-title":"Breast Cancer Res Treat Feb"},{"issue":"8","key":"8043_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/acr.25347","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB et al (2024) 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken) Aug 76(8):1070\u20131082. https:\/\/doi.org\/10.1002\/acr.25347","journal-title":"Arthritis Care Res (Hoboken) Aug"},{"key":"8043_CR22","doi-asserted-by":"publisher","unstructured":"Podolanczuk AJ, Hunninghake GM, Wilson KC et al (2025) Approach to the evaluation and management of interstitial lung abnormalities: an official American thoracic society clinical statement. Am J Respir Crit Care Med 211(7):1132\u20131155. https:\/\/doi.org\/10.1164\/rccm.202505-1054ST","DOI":"10.1164\/rccm.202505-1054ST"},{"issue":"4","key":"8043_CR23","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H et al (2022) Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open Aug 7(4):100554. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554","journal-title":"ESMO Open Aug"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08043-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08043-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08043-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:48:59Z","timestamp":1787640539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08043-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8043"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08043-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was deemed exempt from the WCM IRB.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Pinheiro receives investigator-initiated grant funding from Pfizer and Gilead Sciences.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"34"}}